Optimi Health Sets 2027 Clinical Agenda; Expects First Ibogaine Capsules Soon
Optimi Health (OPTH) outlined 2027 clinical trials for OPTI-101 (psilocybin for MDD) and OPTI-201 (MDMA for PTSD). Phase 2b and 3 trials planned, with U.S. IND applications expected. Ibogaine capsule production to begin soon. Proposed shares-for-debt settlement of US$240,000. OPTH stock is down 5.06% to $1.96.
How this was made

The 30-second read
Why it matters
The amended Phase 2b design for OPTI-101 (controlled trial with an active placebo) and the planned Phase 3 for OPTI-201 provide clearer development milestones, while the shares-for-debt settlement introduces potential dilution and governance considerations. Both factors can influence risk appetite and valuation for OPTH ahead of future regulatory and trial execution steps.
Market read
Traders may reprice OPTH based on the specificity of trial designs, expected dosing/topline windows, and the concrete proposed share issuance tied to unpaid compensation.
What to watch
The proposed shares-for-debt settlement at a fixed $2.10/share could be a near-term dilution signal, and the related-party nature may raise governance scrutiny even if approvals are routine.
Background
Optimi is developing psychedelic-based therapies (psilocybin for MDD, MDMA for PTSD, and ibogaine capsules for prospective research) and is updating its clinical roadmap for 2027.
Ticker impact
Optimi outlined 2027 plans including a Phase 2b OPTI-101 trial in MDD and a Phase 3 OPTI-201 trial in PTSD, plus a proposed shares-for-debt settlement.
Likely two-sided reaction, with upside from clearer trial execution timelines and downside from dilution/settlement overhang and regulatory uncertainty.
The article provides specific amended trial designs, expected dosing and topline windows, and a concrete share issuance price for settling unpaid compensation, but no trial results or regulatory decisions.
Market effects
Reinforces ongoing development momentum in psychedelic-assisted therapies, but does not change sector-wide regulatory expectations.
Limited, as the key catalysts are Canada/US trial planning and Australia supply arrangements.
Low, since the news is company-specific and tied to Health Canada and FDA process steps rather than global policy shifts.
Counterpoint
The timeline is conditional on Health Canada approval and later FDA clearance, so the market may discount the 2027 milestones until regulatory steps are actually completed.
Key entities
- companyOptimi Health Corp.
Subject of the article, outlining 2027 clinical agenda and a proposed shares-for-debt settlement.
- drug_programOPTI-101
Naturally derived psilocybin candidate for major depressive disorder, planned Phase 2b amended protocol.
- drug_programOPTI-201
MDMA-based therapy candidate for PTSD, planned Phase 3 trial in 2027.
- personDane Stevens
CEO involved in the related-party shares-for-debt settlement for unpaid compensation.

